Ophthalmic drug delivery systems—Recent advances

https://doi.org/10.1016/S1350-9462(97)00002-5Get rights and content

Abstract

Eye-drops are the conventional dosage forms that account for 90% of currently accessible ophthalmic formulations. Despite the excellent acceptance by patients, one of the major problems encountered is rapid precorneal drug loss. To improve ocular drug bioavailability, there is a significant effort directed towards new drug delivery systems for ophthalmic administration.

This chapter will focus on three representative areas of ophthalmic drug delivery systems: polymeric gels, colloidal systems, cyclodextrins and collagen shields.

Hydrogels generally offer a moderate improvement of ocular drug bioavailability with the disadvantage of blurring of vision. In situ activated gel-forming systems are preferred as they can be delivered in drop form with sustained release properties. Colloidal systems including liposomes and nanoparticles have the convenience of a drop, which is able to maintain drug activity at its site of action and is suitable for poorly water-soluble drugs. Among the new therapeutic approaches in ophthalmology, cyclodextrins represent an alternative approach to increase the solubility of the drug in solution and to increase corneal permeability. Finally, collagen shields have been developed as a new continuous-delivery system for drugs that provide high and sustained levels of drugs to the cornea, despite a problem of tolerance.

It seems that new tendency of research in ophthalmic drug delivery systems is directed towards a combination of several drug delivery technologies. There is a tendency to develop systems which not only prolong the contact time of the vehicle at the ocular surface, but which at the same time slow down the elimination of the drug. Combination of drug delivery systems could open a new directive for improving results and the therapeutic response of non-efficacious systems.

References (175)

  • I. Ahmed et al.

    Importance of the noncorneal absorption route in topical ophthalmic drug delivery

    Invest. Ophthalmol. Vis. Sci.

    (1985)
  • I. Ahmed et al.

    Disposition of timolol and inulin in the rabbit eye following corneal versus non-corneal absorption

    Int. J. Pharm.

    (1987)
  • A.C. Albertsson et al.

    Preparation and characterization of poly(adipic anhydride) microspheres for ocular drug delivery

    J. Appl. Polymer Science

    (1996)
    A.C Albertsson et al.

    Preparation and characterization of poly(adipic anhydride) microspheres for ocular drug delivery

    J. Appl. Polymer Science

    (1996)
  • A.A. Alghadyan et al.

    Liposome-bound cyclosporine: aqueous and vitreous level after subconjunctival injection

    Int. Ophthalmol.

    (1988)
  • R.C. Allen et al.

    A one-year multicenter clinical trial of pilocarpine gel

    Am. J. Ophthalmol.

    (1984)
  • S. al Mansouri et al.

    Lubrithal (Leo viscous eye gel), precorneal residence time in normal and dry eyes

    Doc. Ophthalmol.

    (1994)
  • M.J. Alonso et al.

    Increased ocular corneal uptake of drugs using poly-ε-caprolactone nanocapsules and nanoemulsions

  • G. Andermann et al.

    Etude comparativé de l'activité antiglaucomateuse de Glauplex 2 et du nitrate de pilocarpine sur le glaucome expérimental à l'alpha-chymotrypsine

    J. Fr. Ophtalmol.

    (1982)
  • D. Ayers et al.

    Polyacrylic acid mediated ocular of ribozymes

    J. Contr. Release

    (1996)
  • M. Barza et al.

    Pharmacokinetics of subconjunctival liposome-encapsulated gentamicin in normal rabbit eves

    Invest. Ophthalmol. Vis. Sci.

    (1984)
  • L.M. Benedetti et al.

    Microspheres of hyaluronic acid esters fabrication methods and in vitro hydrocortisone release

    J. Contr. Release

    (1990)
  • S.F. Bernatchez et al.

    Sodium hyaluronate 0.25% used as vehicle increases the bioavailability of topically administered gentamicin

    Graefes Arch. Clin. Exp. Ophthalmol

    (1993)
  • S.E. Bloomfield et al.

    Soluble gentamicin ophthalmic inserts as a drug delivery system

    Arch. Ophthalmol.

    (1978)
  • W.F. Brechu et al.

    pH and drug ionization affects ocular pressure lowering of topical carbonic anhydrase inhibitors

    Invest. Ophthalmol. Vis. Sci.

    (1993)
  • P. Calvo et al.

    Study of the mechanism of interaction of poly(ε-caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy

    Int. J. Pharm.

    (1994)
  • P. Calvo et al.

    Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers

    J. Pharm. Sci.

    (1996)
  • P. Calvo et al.

    Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A

    Pharm. Res.

    (1996)
  • S.C. Chang et al.

    Relative effectiveness of prodrug and viscous solution approaches in maximizing the ratio of ocular to systemic absorption of topically applied timolol

    Exp. Eye Res.

    (1988)
  • S.C. Chang et al.

    Nasal and conjunctival contributions to the systemic absorption of topical timolol in the pigmented rabbits: implications in the design of strategies to maximize the ratio of ocular to systemic absorption

    J. Ocul. Pharmacol.

    (1987)
  • L. Cheeks et al.

    Influence of vehicle and anterior chamber protein concentration on cyclosporin penetration through the isolated rabbit cornea

    Curr. Eye Res.

    (1992)
  • Y.F. Chen et al.

    Cyclosporine-containing collagen shields suppress corneal allograft rejection

    Am. J. Ophthalmol.

    (1990)
  • S.K. Das et al.

    Evaluation of poly(isobutylcyanoacrylate) nanoparticles for mucoadhesive ocular drug delivery. I. Effect of formulation variables on physicochemical characteristics of nanoparticles

    Pharm. Res.

    (1995)
  • N.M. Davies et al.

    Evaluation of mucoadhesive polymers in ocular drug delivery. I. Viscous solutions

    Pharm. Res.

    (1991)
  • N.M. Davies et al.

    Evaluation of mucoadhesive polymers in ocular drug delivery. II. Polymer-coated vesicles

    Pharm. Res.

    (1992)
  • M. Diaz-Llopis et al.

    Penetration of 2% cyclosporin eye-drops into human aqueous humor

    Br. J. Ophthalmol.

    (1989)
  • M. Diaz-Llopis et al.

    Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients

    Doc. Ophthalmol.

    (1992)
  • K. Dickstein et al.

    Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-age men

    Am. J. Ophthalmol.

    (1996)
  • R. Diepold et al.

    Comparison of different models for the testing of pilocarpine eye-drops using conventional eye-drops and a novel depot formulation (nanoparticles)

    Graefes Arch. Clin. Exp. Ophthalmol.

    (1989)
  • S. Dimitriu et al.

    Polycomponent ophthalmic inserts with polysaccharide support

    J. Bioactive Compatible Polymers

    (1988)
  • M. Dittgen et al.

    Influence of bioadhesion on the elimination of drugs from the eye and on their penetration ability across the pig cornea

    S.T.P. Pharm. Sci.

    (1992)
  • D. Duchêne et al.

    Pharmaceutical and medical aspects of bioadhesive systems of drug administration

    Drug dev. Indust. Pharmacy

    (1988)
  • O. Dudinski et al.

    Acceptability of thickened eye-drops to human subjects

    Curr. Eye Res.

    (1983)
  • A.M. Durrani et al.

    Pilocarpine bioavailability from a mucoadhesive liposomal ophthalmic drug delivery system

    Int. J. Pharm.

    (1992)
  • A.M. Durrani et al.

    Influence of molecular weight and formulation pH on the precorneal clearance rate of hyaluronic acid in rabbit eye

    Int. J. Pharm.

    (1995)
  • H. Fessi et al.

    Nanocapsule formation by interfacial polymer deposition following solvent displacement

    Int. J. Pharm.

    (1989)
  • R. Fiscella et al.

    Duration of therapeutic levels of intravitreally-injected liposome-encapsulated clindamicin in the rabbit

    Can. J. Ophthalmol.

    (1987)
  • P.H. Fishman et al.

    Intravitreal liposome-encapsulated gentamicin in a rabbit model

    Invest. Ophthalmol. Vis. Sci.

    (1986)
  • P. Fitzgerald et al.

    A gamma scintigraphic evaluation of microparticulate ophthalmic delivery systems: liposomes and nanoparticles

    Int. J. Pharm.

    (1987)
  • P. Fitzgerald et al.

    Polymeric systems for ophthalmic drug delivery

  • K.A. Freedman et al.

    Beta-cyclodextrins enhance bioavailability of pilocarpine

    Curr. Eye Res.

    (1993)
  • J.C. Gilbert et al.

    Drug release from Pluronic F-127 gels

    Int. J. Pharm.

    (1986)
  • G.M. Grass et al.

    Mechanisms of corneal drug penetration II: Ultrastructural analysis of potential pathways for drug movement

    J. Pharm. Sci.

    (1988)
  • J.L. Greaves et al.

    Polymers and the precorneal tear film

    S.T.P. Pharm. Sci.

    (1992)
  • J.L. Greaves et al.

    Scintigraphic assessment of an ophthalmic gelling vehicle in man and rabbit

    Curr. Eye Res.

    (1990)
  • F.P. Gunning et al.

    Two topical carbonic anhydrase inhibitors sezolamide and dorzolamide in Gelrite vehicle: a multiple-dose efficacy study

    Graefes Arch. Clin. Exp. Ophthalmol.

    (1993)
  • R. Gurny

    Preliminary study of prolonged acting drug delivery system for the treatment of glaucoma

    Pharm. Acta Helvetica

    (1981)
  • R. Gurny et al.

    Ocular therapy with nanoparticulate systems for controlled drug delivery

    J. Contr. Rel.

    (1985)
  • R. Gurny et al.

    Design and evaluation of controlled release systems for the eye

    J. Contr. Rel.

    (1987)
  • R. Gurny et al.

    The development and use of in situ formed gels triggered by pH

  • R. Gurny et al.

    Precorneal residence time in humans of sodium hyaluronate as measured by gamma scintigraphy

    Graefe's Arch. Clin. Ophthalmol.

    (1990)

    • Cited by (0)

    View full text
    Copyright © 1997 Published by Elsevier Ltd.